Molecular detection of CF lung pathogens: Current status and future potential

被引:19
|
作者
Pattison, Sally H. [1 ,2 ]
Rogers, Geraint B. [3 ]
Crockard, Martin [4 ]
Elborn, J. Stuart [1 ,2 ]
Tunney, Michael M. [1 ,5 ]
机构
[1] Queens Univ Belfast, CF & Airways Microbiol Res Grp, Belfast BT7 1NN, Antrim, North Ireland
[2] Queens Univ Belfast, Sch Med Dent & Biomed Sci, Ctr Infect & Immun, Belfast BT7 1NN, Antrim, North Ireland
[3] Kings Coll London, Mol Microbiol Res Lab, Inst Pharmaceut Sci, London SE1 9NH, England
[4] Randox Labs Ltd, Crumlin, Ireland
[5] Queens Univ Belfast, Sch Pharm, Belfast BT7 1NN, Antrim, North Ireland
关键词
Microbiology; Pathogen; Molecular; Detection; Identification; DESORPTION IONIZATION-TIME; FLIGHT MASS-SPECTROMETRY; CYSTIC-FIBROSIS; PSEUDOMONAS-AERUGINOSA; ANTIMICROBIAL SUSCEPTIBILITY; PULMONARY EXACERBATIONS; BACTERIAL DIVERSITY; IDENTIFICATION; PREVALENCE; CHILDREN;
D O I
10.1016/j.jcf.2013.01.007
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Molecular diagnostic tests, based on the detection and identification of nucleic acids in human biological samples, are increasingly employed in the diagnosis of infectious diseases and may be of future benefit to CF microbiology services. Our growing understanding of the complex polymicrobial nature of CF airway infection has highlighted current and likely future shortcomings in standard diagnostic practices. Failure to detect fastidious or slow growing microbes and misidentification of newly emerging pathogens could potentially be addressed using culture-independent molecular technologies with high target specificity. This review considers existing molecular diagnostic tests in the context of the key requirements for an envisaged CF microbiology focussed assay. The issues of assay speed, throughput, detection of multiple pathogens, data interpretation and antimicrobial susceptibility testing are discussed. (C) 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:194 / 205
页数:12
相关论文
共 50 条
  • [31] Lung cancer chemoprevention: current status and future prospects
    Keith, Robert L.
    Miller, York E.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2013, 10 (06) : 334 - 343
  • [32] Chemoprevention of Lung Cancer: Current Status and Future Prospects
    Victor Cohen
    Fadlo R. Khuri
    Cancer and Metastasis Reviews, 2002, 21 : 349 - 362
  • [33] Conquering lung cancer: current status and prospects for the future
    Pirker, R.
    PULMONOLOGY, 2020, 26 (05): : 283 - 290
  • [34] Current status and future perspectives of SBRT for lung tumours
    Troost, E.
    RADIOTHERAPY AND ONCOLOGY, 2021, 161 : S162 - S163
  • [35] Lung cancer chemoprevention: current status and future directions
    Jenny T. Mao
    Ravi Durvasula
    Current Respiratory Care Reports, 2012, 1 (1): : 9 - 20
  • [36] IMRT for lung cancer: current status and future developments
    Faivre-Finn, C.
    RADIOTHERAPY AND ONCOLOGY, 2016, 119 : S294 - S294
  • [37] Chemoprevention of lung cancer: current status and future prospects
    van Zandwijk, N
    Hirsch, FR
    LUNG CANCER, 2003, 42 : S71 - S79
  • [38] Current Status of Immunotherapy for Lung Cancer and Future Perspectives
    Kim, Ho Cheol
    Choi, Chang-Min
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2020, 83 (01) : 14 - 19
  • [39] Radon and lung cancer: Current status and future prospects
    Liu, Yan
    Xu, Yanqing
    Xu, Wei
    He, Zhengzhong
    Fu, Cong
    Du, Fen
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 198
  • [40] Chemoprevention of lung cancer: Current status and future prospects
    Cohen, V
    Khuri, FR
    CANCER AND METASTASIS REVIEWS, 2002, 21 (3-4) : 349 - 362